Compare EVC & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVC | PRLD |
|---|---|---|
| Founded | 1996 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 335.0M | 391.1M |
| IPO Year | 2000 | 2020 |
| Metric | EVC | PRLD |
|---|---|---|
| Price | $11.59 | $4.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.67 |
| AVG Volume (30 Days) | ★ 2.1M | 560.9K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.35% | N/A |
| EPS Growth | ★ 47.59 | 23.21 |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $536,034,000.00 | $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | $84.08 | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $1.95 | $0.75 |
| 52 Week High | $13.74 | $5.69 |
| Indicator | EVC | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 55.82 | 47.21 |
| Support Level | $2.75 | $3.92 |
| Resistance Level | $13.74 | $4.69 |
| Average True Range (ATR) | 0.88 | 0.45 |
| MACD | -0.23 | -0.04 |
| Stochastic Oscillator | 28.95 | 25.15 |
Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the advertising and technology services segment. Geographically, the company generates the majority of its revenue from the United States.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.